EUVIMEDEUVIMED entdecken
Vergleichsstudie

In Vivo Comparison of Site-Specific and Site-Selective Methods for Pretargeted Imaging in a Murine Model of Colorectal Cancer

Merlin Zabrocki, Samantha Delaney, Lars Hvass iD, Umberto Maria Battisti iD, Andreas Kjær iD, Matthias M Herth iD

Molecular Pharmaceutics · 02.03.2026 · 23 (3) · 2089-2096

DOI: 10.1021/acs.molpharmaceut.5c01802 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Molecular Pharmaceutics, online erschienen am 18.02.2026. Verfasst von Merlin Zabrocki und 5 weiteren Autor:innen. Beteiligte Einrichtung: Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Jagtvej 160, Copenhagen 2100, Denmark. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Immunoconjugates. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: Novo Nordisk Fonden.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pretargeting based on the inverse electron-demand Diels-Alder reaction between a tetrazine and a trans-cyclooctene-modified (TCO) antibody has emerged as a powerful approach to the imaging and therapy of cancer. However, poorly constructed immunoconjugates with TCOs in ill-defined places often leads to suboptimal image contrast in pretargeted immune-PET and SPECT. To address these limitations, site-specific and site-selective approaches to antibody bioconjugation may be used for pretargeted imaging. Herein, we present a comparative study between stochastically, site-specifically, and site-selectively modified immunoconjugates for pretargeted SPECT. First, a trio of immunoconjugates─TCO-CC49, TCO-Gly(Az)CC49, TCO-PFP(Az)CC49─were produced with active TCO moieties sufficient for tetrazine ligation. All immunoconjugates retained high affinity for their target antigen, TAG-72, in enzyme-linked immunosorbent assay experiments and in antigen-expressing tumor tissue. A DOTA-modified tetrazine was labeled with indium-111 in high radiochemical yield and used for in vivo experiments. Then, mice bearing subcutaneous LS 174T xenografts received either TCO-CC49, TCO-Gly(Az)CC49, TCO-PFP(Az)CC49 followed 72 h later by [111In]In-DOTA-Tz (16-20 MBq). SPECT scans were acquired at 1 and 24 h postinjection of radiotracer, and all three constructs produced clear tumor delineation. Ex vivo biodistribution data at 24 h showed [111In]In-DOTA-Tz-TCO-CC49 with the highest tumoral uptake (10.4 ± 1.2% ID/g) probably due to the highest TCO loading, but [111In]In-DOTA-Tz-TCO-Gly(Az)CC49 and [111In]In-DOTA-Tz-TCO-PFP(Az)CC49 increased tumor-to-blood and tumor-to-lung ratios. Ultimately, this comparative study serves as a critical step toward identifying the optimal bioconjugation strategy that may be used in pretargeted systems.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsImmunoconjugatesAnimalsMiceTomography, Emission-Computed, Single-PhotonIndium RadioisotopesFemaleHumansCell Line, TumorPositron-Emission TomographyRadiopharmaceuticalsTissue DistributionDisease Models, AnimalCyclooctanesHeterocyclic Compounds, 1-Ring

Stichwörter der Autor:innen

CC49pretargetingsite-selective conjugationsite-specific conjugationtetrazine ligation SPECT

Substanzen

ImmunoconjugatesIndium RadioisotopesRadiopharmaceuticalsCyclooctanesHeterocyclic Compounds, 1-RingIndium-111

Autor:innen und Institutionen

  • Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Jagtvej 160, Copenhagen 2100, Denmark.
  • Cluster for Molecular Imaging, Department of Biomedical Sciences, University of Copenhagen, Blegdamsvej 3, Copenhagen 2100, Denmark.
  • Department of Clinical Physiology and Nuclear Medicine, Copenhagen University Hospital-Rigshospitalet, Blegdamsvej 9, Copenhagen 2100, Denmark.

ORCID-Profile: Lars Hvass, Umberto Maria Battisti, Andreas Kjær, Matthias M Herth

Förderung

  • Novo Nordisk Fonden

Zitieren

APA

Zabrocki, M., Delaney, S., Hvass, L., Battisti, U. M., Kjær, A., & Herth, M. M. (2026). In Vivo Comparison of Site-Specific and Site-Selective Methods for Pretargeted Imaging in a Murine Model of Colorectal Cancer. Molecular Pharmaceutics, 23(3), 2089-2096. https://doi.org/10.1021/acs.molpharmaceut.5c01802

Vancouver

Zabrocki M, Delaney S, Hvass L, Battisti UM, Kjær A, Herth MM. In Vivo Comparison of Site-Specific and Site-Selective Methods for Pretargeted Imaging in a Murine Model of Colorectal Cancer. Molecular Pharmaceutics. 2026;23(3):2089-2096. doi:10.1021/acs.molpharmaceut.5c01802

BibTeX
@article{Zabrocki2026,
  author = {Zabrocki, Merlin and Delaney, Samantha and Hvass, Lars and Battisti, Umberto Maria and Kjær, Andreas and Herth, Matthias M},
  title = {In Vivo Comparison of Site-Specific and Site-Selective Methods for Pretargeted Imaging in a Murine Model of Colorectal Cancer},
  journal = {Molecular Pharmaceutics},
  year = {2026},
  volume = {23},
  number = {3},
  pages = {2089--2096},
  doi = {10.1021/acs.molpharmaceut.5c01802}
}
Kostenlos starten →